# A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)

> **NCT02296476** · PHASE2 · TERMINATED · sponsor: **Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 12 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Birabresib

## Key facts

- **NCT ID:** NCT02296476
- **Lead sponsor:** Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-10-29
- **Primary completion:** 2015-10-20
- **Final completion:** 2015-10-20
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** This study was terminated due to lack of clinical activity and not due to safety reasons.
- **Last updated:** 2021-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02296476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02296476, "A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02296476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*